Back to Trades
Fust Matthew K
DirectorCIK 0001397266
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 6
- Buy transactions
- 0
- Sell transactions
- 1
- Companies
- 4
- Active
- 2025–2026
Across 6 filings between 2025–2026, Fust Matthew K, Director, has disclosed $5.7M in transactions — spread across 4 companies. Their disclosed trades are heavily weighted toward selling — $0 in buys and $716.0K in sells. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
6 loaded
| Sep 1 | CRNX Crinetics Pharmaceuticals, Inc. | Fust Matthew K | Director | Disposed | $4.0M |
| Jun 22 | CRNX Crinetics Pharmaceuticals, Inc. | Fust Matthew K | Director | Grant | $349.0K |
| Jun 11 | ATRA Atara Biotherapeutics, Inc. | Fust Matthew K | Insider | Grant | $0 |
| May 29 | NMRA Neumora Therapeutics, Inc. | Fust Matthew K | Insider | Award | $148.8K |
| May 18 | RARE Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Insider | Grant | $362.7K |
| Sep 30 | CRNX Crinetics Pharmaceuticals, Inc. | Fust Matthew K | Director | Sell | $716.0K |
6 filings